Compare ANIK & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIK | SWKH |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Medical/Dental Instruments | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.6M | 198.4M |
| IPO Year | 1996 | N/A |
| Metric | ANIK | SWKH |
|---|---|---|
| Price | $14.97 | $15.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $17.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 115.6K | 104.8K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $112,819,000.00 | N/A |
| Revenue This Year | $5.98 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $13.32 |
| 52 Week High | $16.24 | $17.90 |
| Indicator | ANIK | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 32.19 |
| Support Level | $13.81 | $14.69 |
| Resistance Level | $15.74 | $17.08 |
| Average True Range (ATR) | 0.93 | 0.37 |
| MACD | -0.16 | -0.05 |
| Stochastic Oscillator | 69.44 | 12.06 |
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.